Rosnilimab
Rheumatoid Arthritis (RA)
Phase 1Active
Key Facts
About AnaptysBio
AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis (RA) Drugs
| Drug | Company | Phase |
|---|---|---|
| SPY072 | Spyre Therapeutics | Phase 2 |
| CLN-978 | Cullinan Therapeutics | Phase 1 |
| Telitacicept | Vor Biopharma | Marketed |
| ABO21009 | AboleIIs Pharma | Phase 1 |